Taysha Gene Therapies (NASDAQ:TSHA) has received mixed reviews from 7 financial analysts over the past quarter, with ratings ranging from bullish to bearish. The average 12-month price target for TSHA has been raised to $6.71, indicating a 34.2% increase from the previous target of $5.00. Analysts from firms including Piper Sandler, Canaccord Genuity, Chardan Capital, JMP Securities, Cantor Fitzgerald, and Needham have provided updates, with actions ranging from maintaining to raising their price targets. Taysha Gene Therapies, a gene therapy company focused on CNS diseases, has shown notable financial performance with a revenue growth of 44.04%, an impressive net margin of 1324.67%, and a high ROE of 369.76%, despite a high debt-to-equity ratio of 0.82.